We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Reprogramming Stem Cells May Suppress Cancer after Radiotherapy

By MedImaging International staff writers
Posted on 27 Jan 2015
Print article
The body has developed strategies of purging defective stem cells. A new study has revealed that one of these ways is a “program” that makes stem cells damaged by radiation differentiate into other cells that can no longer survive forever.

Radiation makes a stem cell lose its “stemness,” which makes sense because damaged stem cells do not need to hang around to pump out damaged cells. Moreover, the research, conducted by University of Colorado (CU) Cancer Center (Aurora, USA) scientists, and published online December 27, 2014, in the journal Stem Cells, demonstrated that this same protection of “programmed mediocrity” that rids stem cells damaged by radiation allows blood cancers to grow in instances when the total body is irradiated. Furthermore, by reprogramming this defense, cancer may be prevented in the aftermath of full body radiation. “The body didn’t evolve to deal with leaking nuclear reactors and CT scans. It evolved to deal with only a few cells at a time receiving dangerous doses of radiation or other insults to their DNA,” said James DeGregori, PhD, investigator at the CU Cancer Center, professor of biochemistry and molecular genetics at the CU School of Medicine, and the article’s senior author.

Dr. DeGregori, doctoral student Courtney Fleenor, and colleagues examined the effects of full body radiation on the blood stem cells of mice. In this case, radiation increased the probability that cells in the hematopoietic stem cell system would differentiate. Only, while most obeyed this instruction, a few did not. Stem cells with a very specific mutation were able to disobey the instruction to differentiate and retain their “stemness.” Genetic inhibition of the gene C/EBPA allowed a few stem cells to keep the ability to act as stem cells. With competition from other, healthy stem cells removed, the stem cells with reduced C/EBPA were able to dominate the blood cell production system. In this way, the blood system transitioned from C/EBPA+ cells to primarily C/EBPA- cells.

Mutations and other genetic alterations resulting in inhibition of the C/EBPA gene are associated with acute myeloid leukemia in humans. Thus, it's not mutations caused by radiation but a blood system reengineered by faulty stem cells that creates cancer risk in people who have experienced radiation. “It’s about evolution driven by natural selection,” Dr. DeGregori noted. “In a healthy blood system, healthy stem cells out-compete stem cells that happen to have the C/EBPA mutation. But when radiation reduces the heath and robustness of the stem cell population, the mutated cells that have been there all along are suddenly given the opportunity to take over.”

These studies do not only clarify why radiation makes hematopoietic stem cells (HSCs) differentiate; they also show that by activating a stem cell maintenance pathway, we can keep it from happening. Even months after irradiation, artificially activating the NOTCH signaling pathway of irradiated HSCs lets them act “stemmy” again—restarting the blood cell assembly line in these HSCs that would have otherwise differentiated in response to radiation.

When Drs. DeGregori, Fleenor and colleagues triggered NOTCH in earlier irradiated HSCs, it kept the population of dangerous, C/EBPA cells at bay. Competition from non-C/EBPA-mutant stem cells, with their health restored by NOTCH activation, meant that there was no evolutionary space for C/EBPA-mutant stem cells.

“If I were working in a situation in which I was likely to experience full-body radiation, I would freeze a bunch of my HSCs,” Dr. DeGregori stated, explaining that an infusion of healthy HSCs after radiation exposure would likely allow the healthy blood system to out-compete the radiation-exposed HSC with their ‘programmed mediocrity’ [increased differentiation] and even HSC with cancer-causing mutations. “But there’s also hope that in the future, we could offer drugs that would restore the fitness of stem cells left over after radiation.”

Related Links:

University of Colorado Cancer Center


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
X-Ray Detector
FDR-D-EVO III
Under Table Shield
3 Section Double Pivot Under Table Shield
Dose Area Product Meter
VacuDAP

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.